BONESUPPORT RECEIVES APPROVAL TO MARKET CERAMENTT IN INDIA CERAMENTTIG is the first injectable antibiotic eluting bone substitute in India

Osteomyelitis, or Bone Infection is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries, and an increasing resistance to antibiotics contribute to this growing condition.

 With the population of India exceeding a billion people, this approval represents one of the more significant international markets for CERAMENTT and is an important step in our geographic expansion plan,” said Vikram Johri, Executive Vice President International at BONESUPPORT.  “In a country where synthetic bone void fillers are widely accepted, quality is gaining importance as regulations increase.  In addition, the combination of an antibiotic loaded product that promotes bone healing and remodeling presents an important clinical option in a country with a high rate of bone infection and limb salvage procedures.”

According to the 2014 IDF Diabetes Atlas, middle and low-income countries often have higher rates of adult diabetes compared to the world average.  In India, more than 66 million adults have been diagnosed with the disease in addition to an estimated 35 million undiagnosed cases.  It’s expected that more than 10% of diabetic sufferers will be afflicted with osteomyelitis due to diabetic foot ulcers.

“The CERAMENTT platform has a long standing safety profile and we are pleased to see this once again confirmed by India’s approval,” said Lloyd Diamond, CEO of BONESUPPORT.  “CERAMENTT’G is an important advancement in the management of bone infections and we are proud to be at the forefront in addressing an unmet need to patients in India.”


BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute.  CERAMENTT’G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries.  CERAMENTT’G is not available in the United States.

CERAMENTT is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and close to 9,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Phone +46 46 286 53 60
PR 0409-01 en


90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge